Study on Use of Avelumab in Combination with Crizotinib or Lorlatinib in Patients with NSCLC. A Phase 1b/2, Open-Label, Dose Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination With Either Crizotinib or PF-06463922 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer.